Inari Medical, Inc. (NARI)
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Investigation
10/14/2021
Initial Lawsuit
10/14/2021
Lawsuit Progression
12/13/2021
Investigation regarding InnovAge’s statements about its services and subsequent failures and deficiencies identified by the CMS.
09/21/2021
InnovAge discloses its Q4 and 2021 financial results. In a conference call to discuss the results, the company reveals that following the Centers for Medicare and Medicaid Services’ (CMS) routine scheduled audit of its Sacramento center, the CMS decided to freeze new enrollments.
“This past Friday, September 17, we were notified the CMS has determined to freeze new enrollments at our Sacramento center based on deficiencies detected in the audit. The deficiencies relate to failures to provide covered services, provide accessible and adequate services, manage participants medical situations, and oversee use of specialists among others. The freeze will remain in effect until we correct these deficiencies and we are working on developing a corrective action plan to submit to CMS.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$8.75 | $11.65 | $-2.9 | -24.89% |
This is a class action on behalf of persons and entities that purchased or otherwise acquired InnovAge common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s March 2021 initial public offering (IPO).
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(1) that certain of InnovAge’s facilities failed to provide covered services, provide accessible and adequate services, manage participants’ medical situations, and oversee use of specialists;
(2) that, as a result, the Company was reasonably likely to be subject to regulatory scrutiny, including by the Centers for Medicare and Medicaid Services;
(3) that, as a result, there as a significant risk that CMS would suspend new enrollments pending an audit of the Company’s services; and
(4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
The lead plaintiff deadline has passed, we will update this page as the lawsuit progresses.
Last event retrieved on 10/04/2022.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.